Navigation Links
Canadian scientist develops world's most advanced drug to protect the brain after a stroke
Date:2/29/2012

Toronto, February 29, 2012 - Scientists at the Toronto Western Research Institute (TWRI), Krembil Neuroscience Center, have developed a drug that protects the brain against the damaging effects of a stroke in a lab setting. This drug has been in development for a few years. At this point, it has reached the most advanced stage of development among drugs created to reduce the brain's vulnerability to stroke damage (termed a "neuroprotectant"). Over 1000 attempts to develop such drugs by scientists worldwide have failed to be translated to a stage where they can be used in humans, leaving a major unmet need for stroke treatment. The drug developed by the TWRI team is the first to achieve a neuroprotective effect in the complex brain of primates, in settings that simulate those of human strokes. ischemic stroke.

The study, "Treatment of Stroke with a PSD95 inhibitor in the Gyrencephalic Primate Brain", published online today in Nature, shows how the drug, called a "PSD95 inhibitor" prevents brain cell death and preserves brain function when administered after a stroke has occurred.

"We are closer to having a treatment for stroke than we have ever been before," said Dr. Michael Tymianski, TWRI Senior Scientist and the study's lead author. "Stroke is the leading cause of death and disability worldwide and we believe that we now have a way to dramatically reduce its damaging effects."

During a stroke, regions of the brain are deprived of blood and oxygen. This causes a complex sequence of chemical reactions in the brain, which can result in neurological impairment or death. The PSD95 inhibitor published by the Toronto team acts to protect the brain by preventing the occurrence of these neurotoxic reactions.

The study used cynomolgus macaques, which bear genetic, anatomic and behaviour similarities to humans, as an ideal model to determine if this therapy would be beneficial in patients.

Animals that were treated with the PSD95 inhibitor after a stroke had greatly reduced brain damage and this translated to a preservation of neurological function. These improvements were observed in several scenarios that simulated human strokes. Specifically, when the treatment was given either early, or even at 3 hours, after the stroke onset, the animals exhibited remarkable recoveries. Benefits were also observed when the drug therapy was combined with conventional therapies (aimed at re-opening blocked arteries to the brain). Beneficial effects were observed even in a time window when conventional therapies on their own no longer have an effect.

"There is hope that this new drug could be used in conjunction with other treatments, such as thrombolytic agents or other means to restore blood flow to the brain, in order to further reduce the impact of stroke on patients," said Dr. Tymianski. "These findings are extremely exciting and our next step is to confirm these results in a clinical trial."


'/>"/>

Contact: Nadia Daniell-Colarossi
nadia.daniell-colarossi@uhn.on.ca
416-603-5294
University Health Network
Source:Eurekalert

Related medicine news :

1. Canadian Isotope Project enters final stretch
2. 1 in 10 Canadians cannot afford prescription drugs: UBC study
3. Warwick joins $3.4 million Anglo-Canadian quest for new weapons in war against antibiotic resistance
4. New Canadian Guidelines Also Support No Routine Mammograms Until 50
5. Canadian breast cancer screening guidelines would cost thousands of lives
6. Canadian Diabetes Association announces Elsevier as new publisher of Canadian Journal of Diabetes
7. Canadian researchers find potential new leukemia treatment with old antibiotic drug
8. Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades
9. Canadian Journal of Cardiology publishes report on delayed vs. immediate coronary stenting
10. How hemp got high: Canadian scientists map the cannabis genome
11. Fatal crashes in the US: Fewer Canadian drivers under the influence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to ... shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and educational ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... torn anterior cruciate ligament (ACL) offer patients improved quality of life five years ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology: